Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Alexion Pharmaceuticals

Expand the AG10 program into Japan

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced
23 Oct 2019
Due
31 Dec 2020
Delivered
Q4 2020
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Alexion plans to expand the AG10 program into Japan in 2020, pending regulatory feedback.”

What we found

Evidence strength A What the grades mean

Alexion initiated a single-arm AG10 Phase III study in ATTR-CM in Japan during the fourth quarter of 2020, fulfilling the commitment to expand the program into Japan within the 2020 timeframe.

  • A
    Alexion Pharmaceuticals 10-K filed 2021-02-08 Regulatory filing · published 8 Feb 2021 · retrieved 21 Oct 2026 · kept permanently by the SEC · fingerprint 10caf5605550
    “In the fourth quarter 2020, Alexion initiated a single arm AG10 Phase III study in ATTR-CM in Japan.” ✓ confirmed on the page

Checked 21 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Rollout
Indicative materiality
Low rules
Action
Expand
Deliverable
AG10 program expansion into Japan
Where
Japan
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
High
Conditional
Yes: pending regulatory feedback
Depends on
Regulatory

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
  3. Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2019-C899866-019353 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.